Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Sestrin2 contributes to BRAF inhibitor resistance via reducing redox vulnerability of melanoma cells.

Journal of dermatological science - 1 Feb 2023

Guo Sen, Yue Qiao, Wang Shiyu, Wang Huina, Ye Zhubiao, Zhang Weigang, Shi Qiong, Gao Tianwen, Li Chunying, Zhu Guannan

Abstract excerpt

BACKGROUND: Treatment resistance often occurs with BRAF inhibitor (BRAFi) therapy for melanoma, bringing in a great challenge to the treatment of melanoma patients harboring mutant BRAF gene. Recent studies revealed redox vulnerability constitutes a novel opportunity to overcome BRAFi resistance. Previously we found Sestrin2 provided protection to metastatic melanoma cells by detoxifying reactive oxygen species...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Line, Tumor
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Melanoma

Share to Oxidation-Reduction

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins B-raf

Share to TOR Serine-Threonine Kinases

Share to Vemurafenib

Source

Identifiers

PMID: 36858850
DOI: 10.1016/j.jdermsci.2022.12.007

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Sestrin2 contributes to BRAF inhibitor resistance via reducing redox vulnerability of melanoma cells.PMID 36858850Read ↗

The Role of Senescent Cells in Acquired Drug Resistance and Secondary Cancer in BRAFi-Treated MelanomaSemantic proximity Read ↗

Implication of Unfolded Protein Response and Autophagy in the Treatment of BRAF Inhibitor Resistant Melanoma.Semantic proximity Read ↗

An Acquired Vulnerability of Drug-Resistant Melanoma with Therapeutic Potential.Semantic proximity Read ↗

A Review of the Molecular Pathways Involved in Resistance to BRAF Inhibitors in Patients with Advanced-Stage Melanoma.Semantic proximity Read ↗

RSK2 promotes melanoma cell proliferation and vemurafenib resistance via upregulating cyclin D1Semantic proximity Read ↗

Multi-omics analysis delineates resistance mechanisms associated with BRAF inhibition in melanoma cells.Semantic proximity Read ↗

miR-410-3p is induced by vemurafenib via ER stress and contributes to resistance to BRAF inhibitor in melanomaSemantic proximity Read ↗

Disrupting peroxisomes alters lipid metabolism in melanoma and uncovers a novel therapeutic vulnerability in combination with MAPK-targeted therapiesSemantic proximity Read ↗

Redirecting resistance evolution in <i> BRAF <sup>V600</sup> </i> melanoma by inhibition of the peroxiredoxin-thioredoxin systemSemantic proximity Read ↗

Dual Specificity Phosphatase 1 (DUSP1) Provides Mechanistic Link Between Melanoma Cellular Plasticity and Drug ResistanceSemantic proximity Read ↗

PTRF Confers Melanoma‐Acquired Drug Resistance Through the Upregulation of EGFRSemantic proximity Read ↗

Increased inflammatory lipid metabolism and anaplerotic mitochondrial activation follow acquired resistance to vemurafenib in BRAF-mutant melanoma cells.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.